Clinical Trials Logo

Myocardial Reperfusion Injury clinical trials

View clinical trials related to Myocardial Reperfusion Injury.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06450912 Completed - Clinical trials for Acute Myocardial Infarction

Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction

MIRON-STRAIN
Start date: June 1, 2022
Phase:
Study type: Observational

Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Wall motion index ratio is an important parameter to determine regions of high vulnerability within the 17-segment LV model of hemorrhagic MI.

NCT ID: NCT06373549 Completed - Clinical trials for Cardiovascular Diseases

Investigation of Myocardial Protection Efficacy of Cardioplegia Solutions Used in Open Heart Surgery

Start date: December 8, 2022
Phase:
Study type: Observational

Cardioplegias are different pharmacokinetic solutions routinely used in cardiac surgery to protect the heart from ischemia and induce arrest. Various cardioplegia solutions (such as Bretschneider, del Nido, blood cardioplegia, crystalloid cardioplegia, St. Thomas) are used in clinical practice. There is no clear scientific data in the literature that demonstrates the superiority of one cardioplegia over the others. The choice of the appropriate cardioplegia depends on the surgeon's clinical experience and preference. In this study preferred the blood cardioplegia and del Nido cardioplegia, which are commonly used in clinic. Both cardioplegias have different advantages that contribute to their preference in clinical practice. Blood cardioplegia is an autologous cardioplegia that includes physiological buffer systems, allowing for heart nourishment and containing native antioxidant systems. However, the need for repeated doses every 20 minutes after the initial application creates a disadvantage in terms of surgical comfort. On the other hand, del Nido cardioplegia is preferred by surgeons in complex cases due to its long application intervals. The adequacy of a single dose for up to 90 minutes after the initial application creates an advantage in terms of surgical comfort and surgical integrity. However, the content being predominantly electrolyte-based, containing 1:4 ratio of autologous blood, and the extended time of a single dose are disadvantages compared to blood cardioplegia in terms of heart nourishment and protection from ischemia. In addition to these different usage scenarios, the myocardial protective effects of cardioplegias on cellular redox homeostasis are also among the current research topics. Thesis project can contribute to the current literature and clinical practice on the cardioprotective advantages of cardioplegia solutions and the reasons for their preference in surgery.

NCT ID: NCT05354648 Completed - Clinical trials for Coronary Artery Disease

Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical Patients

Start date: June 1, 2015
Phase: N/A
Study type: Interventional

Coronary artery bypass grafting (CABG) with cardiopulmonary bypass is a common surgical therapy for patients suffering from coronary artery diseases. The heart is subjected to a long period of ischemia due to the occlusion of the aorta. The heavy burden of myocardial ischemia-reperfusion injury (IRI) thus induces cardiomyocyte death, which can paradoxically reduce the beneficial effect of CABG. Preconditioning by moderate hypoxia or hyperoxia serves as an effective drug-free method to increase the organism's resistance to negative effects, including IRI.

NCT ID: NCT05215743 Completed - Clinical trials for Acute Myocardial Infarction

Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.

Start date: August 9, 2022
Phase: Phase 1
Study type: Interventional

Background: Acute myocardial infarction (AMI) has remained a leading cause of mortality and disability worldwide. Although percutaneous coronary angioplasty (PCA) is the best treatment for these patients, paradoxically this procedure causes reperfusion injury. Considerable efforts aimed to reduce this damage have been made, but the results are disappointing and there is still no effective therapy for preventing the damage. Previously, the investigators have achieved a reduction of infarct size in an experimental model of an isolated rat heart, through a synergistic effect of three compounds in a "combined antioxidant therapy" (CAT). In this study, the investigators aim to describe the pharmacokinetics and safety of CAT intravenously administered to healthy subjects. This is the first step to a later clinical application of CAT in AMI patients. Methodology: The safety and pharmacokinetics of the CAT (deferoxamine, N-acetylcysteine, and ascorbate) will be assessed in healthy volunteers in a "phase I clinical trial". Two different formulations (mass of CAT components by bag) with different infusion rates each one will be tested (CAT1 and CAT2). Subjects (18-35 years old, n=18) will be randomized 1:2 to receive a placebo or CAT for 90 minutes. Blood concentrations of each CAT component will be measured in plasma at 0, 15, 30, 60, 90, 120, and 180 minutes after the infusion onset. Adverse events will be registered from the onset of infusion until day 30.

NCT ID: NCT04397939 Completed - COVID-19 Clinical Trials

Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19

Start date: May 8, 2020
Phase:
Study type: Observational

The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

NCT ID: NCT03500783 Completed - Clinical trials for Coronary Artery Disease

Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass

NOinCPB
Start date: May 15, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This prospective randomized study elucidates the effects of exogenous nitric oxide delivered to the extracorporeal circulation circuit for cardioprotection against ischemia-reperfusion injury during coronary artery bypass graft surgery with cardiopulmonary bypass.

NCT ID: NCT03050489 Completed - Clinical trials for Coronary Artery Disease

Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG

Start date: September 15, 2015
Phase:
Study type: Observational

Assessment of myocardial ischemic-reperfusion injury during off- and on- pump CABG.

NCT ID: NCT02993484 Completed - Clinical trials for Reperfusion Injuries, Myocardial

The Role of Mitochondrial Respiration in the Cardioprotective Capacity of IPC in Diabetic and Non-diabetic Patients

Start date: December 2016
Phase: N/A
Study type: Interventional

The overall aim of this study is to examine the role of mitochondrial respiration in human diabetic tissue before and after ischemia. Furthermore we will examine the ability of ischemic preconditioning (IPC) to preserve the mitochondrial function and hemodynamic performance of both non-diabetic and diabetic fibers after ischemia. To increase our understanding on the metabolic changes during ischemia in both non-diabetic and diabetic tissue we will use Dimethyl Malonate and examine the impact of this blockade on post-ischemic mitochondrial respiration.

NCT ID: NCT02984111 Completed - Clinical trials for Myocardial Ischemic Reperfusion Injury

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

Start date: January 2016
Phase: N/A
Study type: Interventional

The aim of this trail is to assess the safety and therapeutic effects of single EPO intervention in different times during coronary surgery in changes of inflammatory response.

NCT ID: NCT02405689 Completed - Clinical trials for Myocardial Ischemic Reperfusion Injury

Myocardial Protection and Anesthetic Agents

Start date: December 2014
Phase: Phase 4
Study type: Interventional

The aim of this study was to investigate the myocardial protective effects of remifentanil and dexmedetomidine in cardiac surgery.